88ºF

Beaumont launches new clinical study on combo treatment for COVID-19

Beaumont Health launches coronavirus hotline for patients with symptoms, puts visitor restrictions in place
Beaumont Health launches coronavirus hotline for patients with symptoms, puts visitor restrictions in place

DETROIT – Beaumont Health has launched a new clinical study aimed at treating COVID-19 patients with two common drugs – naltrexone and ketamine.

Beaumont says it received FDA approval to operate the new clinical trial at Beaumont Hospital in Royal Oak.

The study, called “SINK COVID-19,” or the Study of Immunomodulation using Naltrexone and Ketamine for COVID-19, is a randomized study for patients 18 and older.

Beaumont researchers say they are hopeful the two drugs can lessen the severity of COVID-19 symptoms by reducing the early and later side effects of the virus.

Related: Beaumont Health launches study on coronavirus (COVID-19) antibodies

“There is an urgent need to develop new treatments for COVID-19 using easily available and affordable medications,” said Dr. Matthew Sims, director, Infectious Disease Research, Beaumont Health and study principal investigator. “Ideal new treatments for COVID-19 would help halt the progression of the disease in patients with mild cases prior to the need for ventilators, and provide a rescue treatment for patients with severe cases of the virus.”

Dr. Annas Aljassem, study co-investigator, said, “We need a two-pronged strategy to combat COVID-19. Low doses of naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms.”

Low-dose naltrexone has been used for the treatment of pain and inflammation in multiple sclerosis, Crohn’s disease, fibromyalgia and other pain conditions. Ketamine, an anesthetic drug, shows anti-inflammatory effects at multiple early steps in the inflammatory process.

“The addition of these two medications, as immunomodulators, to the treatment regimen of patients with COVID-19 has potential to decrease the severity of this disease by reducing the autoimmune, hyperinflammatory stages of the virus which is destructive to normal tissue and, when unchecked, rapidly leads to death,” Dr. Sims said.

Find the latest COVID-19 data here.


About the Author: